EUCTR2007-004320-21-SK进行中（未招募）1 期
OPEN LABEL EXTENSION STUDY EVALUATING THE SAFETY AND BIOLOGICAL ACTIVITY OF A NEW PROLONGED RELEASE FORMULATION OF OCTREOTIDE ACETATE, C2L-OCT-01 PR, ADMINISTERED INTRA MUSCULARLY EVERY 6, 5 0R 4 WEEKS IN ACROMEGALIC PATIENTS
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 61
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients having completed the 24 week study C2L-OCT-01 PR-301 (protocol version 3, 8 May 2007)
- •Women of childbearing potential must have a negative pregnancy test.
- •Having the ability to understand the requirements of the study, provide written informed consent to participate in this study, and agree to abide by the study restrictions.
- •Entry criteria for participation in Extension Study Part B:
- •Patients having completed the first 6 month study C2L-OCT-01 PR-302 of Part A
- •Women of childbearing potential must have a negative urine pregnancy test.
- •Patients having the ability to understand the requirements of the study.
- •Patients who:
- •have achieved a mean GH value < 2.5 ng/ml from baseline (Day 1 of study C2L-OCT-01 PR-301)
- •have a decrease of GH mean value of at least 30% from baseline (Day 1 of study C2L-OCT-01 PR-301) and have an improvement in their clinical symptoms based on investigator’s judgment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Female patients of childbearing potential age who are not using adequate contraception. (i.e. oral or trans-dermal contraceptive drugs, intra-uterine device, diaphragm)
- •Pregnant or lactating female patients.
- •Having experienced any clinically significant adverse event related to study medication in the C2L-OCT-01 PR-301 (version 3, 8 May 2007).
- •Patients with uncontrolled Diabetes type II as indicated by the presence of ketoacidosis or HbA1C = 10%.
- •Presenting clinically significant signs and symptoms potentially related to a tumor compression of the optical chiasm, based on judgment of the investigator.
- •Patients with symptomatic cholelithiasis.
- •Presenting clinically serious and/or unstable intercurrent infection, medical illnesses or conditions that are uncontrolled or whose control, in the opinion of the Investigator, may be jeopardized by participation in this study or by the complications of this therapy.
研究者
相似试验
进行中（未招募）
不适用
OPEN LABEL EXTENSION STUDY EVALUATING THE SAFETY AND BIOLOGICAL ACTIVITY OF A NEW PROLONGED RELEASE FORMULATION OF OCTREOTIDE ACETATE, C2L-OCT-01 PR, ADMINISTERED INTRA MUSCULARLY EVERY 6 WEEKS IN ACROMEGALIC PATIENTSMedDRA version: 9.1Level: LLTClassification code 10000599Term: AcromegalyAcromegalyEUCTR2007-004320-21-HUAmbrilia Biopharma Inc.58
进行中（未招募）
1 期
OPEN-LABEL EXTENSION STUDY TO ASSESS THE SAFETY AND LONG-TERM EFFECTIVENESS OF ORALLY ADMINISTERED EFAVIRENZ IN PATIENTS DIAGNOSED WITH ADULT OR LATE-ONSET JUVENILE TYPE C NIEMANN-PICK DISEASE WITH COGNITIVE IMPAIRMENTType C Niemann-Pick DiseaseMedDRA version: 20.0Level: PTClassification code: 10029403Term: Niemann-Pick disease Class: 100000004850CTIS2023-505832-36-01Bellvitge University Hospital16
进行中（未招募）
不适用
uncontrolled epilepsyEUCTR2009-017904-95-DEpsher-Smith Laboratories, Inc.275
进行中（未招募）
不适用
Open-Label Extension Study to Evaluate the Safety of USL255 as Adjunctive Therapy in Patients with Refractory Partial-Onset Seizures who had Participated in P09-004, a Randomized, Multicenter, Double-Blind, Placebo–Controlled, Parallel-Group, Phase 3 StudyRefractory partial-onset seizures with or without secondary generalizationMedDRA version: 14.0Level: PTClassification code 10056209Term: Partial seizures with secondary generalisationSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: PTClassification code 10040703Term: Simple partial seizuresSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: LLTClassification code 10034090Term: Partial seizures, complexSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: LLTClassification code 10048674Term: Partial seizures with secondary generalizationSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: PTClassification code 10010145Term: Complex partial seizuresSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: LLTClassification code 10034091Term: Partial seizures, simpleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-017904-95-GRpsher-Smith Laboratories, Inc.172
进行中（未招募）
不适用
Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset SeizuresRefractory partial-onset seizures with or without secondary generalizationMedDRA version: 14.0Level: PTClassification code 10056209Term: Partial seizures with secondary generalisationSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: PTClassification code 10040703Term: Simple partial seizuresSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: LLTClassification code 10034090Term: Partial seizures, complexSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: LLTClassification code 10048674Term: Partial seizures with secondary generalizationSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: PTClassification code 10010145Term: Complex partial seizuresSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: LLTClassification code 10034091Term: Partial seizures, simpleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-017904-95-HUpsher-Smith Laboratories, Inc.172